Lotte Spekhorst
5PUBLICATIONS
16CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Oct 25, 2024
Type 2 Immune-Dominant Endotype Is Not Associated With Increased Responsiveness to Dupilumab Treatment in Adult Atopic Dermatitis Patients.Coco Dekkers, Hidde Smits, Dora Stölzl
|Nov 24, 2022
Dupilumab has a profound effect on specific-IgE levels of several food allergens in atopic dermatitis patients.Lotte S Spekhorst, Lisa P van der Rijst, Marlies de Graaf
|Jul 15, 2022
Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis.Lotte S Spekhorst, Daphne Bakker, Julia Drylewicz
|Apr 18, 2020
Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry.Lotte S Spekhorst, Lieneke F M Ariëns, Jorien van der Schaft
|Dec 30, 2018
Determinants of omalizumab drug survival in a long-term daily practice cohort of patients with chronic urticaria.L S Spekhorst, J M P A van den Reek, A C Knulst
Pageof 1
Frequent Collaborators
4 joint publications
Marjolein S de Bruin-Weller
3 joint publications
Judith Thijs
2 joint publications
Daphne Bakker
2 joint publications
Julia Drylewicz
1 joint publications
H Röckmann
1 joint publications
Lieneke F M Ariëns
1 joint publications
Coco Dekkers
1 joint publications
Hidde Smits
1 joint publications
Dora Stölzl
1 joint publications
Edward Knol
